18 Citations (Scopus)

Abstract

Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6% fiveyear survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for miRNA profiling and targeting in aiding PC treatment.

Original languageEnglish (US)
Pages (from-to)1101-1109
Number of pages9
JournalCurrent drug targets
Volume14
Issue number10
DOIs
StatePublished - Aug 15 2013

Fingerprint

MicroRNAs
Pancreatic Neoplasms
Therapeutics
Oncology
Chemotherapy
Neoplasm Metastasis
Drug Therapy
Neoplasms

Keywords

  • MiRNA
  • Pancreatic cancer
  • Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Prospects of miRNA-based therapy for pancreatic cancer. / Pai, Priya; Rachagani, Satyanarayana; Are, Chandrakanth; Batra, Surinder Kumar.

In: Current drug targets, Vol. 14, No. 10, 15.08.2013, p. 1101-1109.

Research output: Contribution to journalReview article

@article{1496fddba4d1449d98719fbc30674bf1,
title = "Prospects of miRNA-based therapy for pancreatic cancer",
abstract = "Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6{\%} fiveyear survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for miRNA profiling and targeting in aiding PC treatment.",
keywords = "MiRNA, Pancreatic cancer, Therapy",
author = "Priya Pai and Satyanarayana Rachagani and Chandrakanth Are and Batra, {Surinder Kumar}",
year = "2013",
month = "8",
day = "15",
doi = "10.2174/13894501113149990181",
language = "English (US)",
volume = "14",
pages = "1101--1109",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Prospects of miRNA-based therapy for pancreatic cancer

AU - Pai, Priya

AU - Rachagani, Satyanarayana

AU - Are, Chandrakanth

AU - Batra, Surinder Kumar

PY - 2013/8/15

Y1 - 2013/8/15

N2 - Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6% fiveyear survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for miRNA profiling and targeting in aiding PC treatment.

AB - Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6% fiveyear survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for miRNA profiling and targeting in aiding PC treatment.

KW - MiRNA

KW - Pancreatic cancer

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84881357000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881357000&partnerID=8YFLogxK

U2 - 10.2174/13894501113149990181

DO - 10.2174/13894501113149990181

M3 - Review article

C2 - 23834151

AN - SCOPUS:84881357000

VL - 14

SP - 1101

EP - 1109

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -